A Phase II, Open Label, Single Arm Study of i.v. Panobinostat (LBH589) in Patients With Metastatic Hormone Refractory Prostate Cancer.

Trial Profile

A Phase II, Open Label, Single Arm Study of i.v. Panobinostat (LBH589) in Patients With Metastatic Hormone Refractory Prostate Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2013

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Jun 2010 Planned end date changed from 1 Mar 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
    • 03 Jul 2009 Planned end date (Mar 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top